• Histologically confirmed epithelial cancer of the following tumor types: breast (TNBC, HR+/HER2-/+BC), NSCLC, cervical, CRPC, PDAC, HNSCC, endometrial, ovarian, gastric/GEJ, or urothelial that is unresectable, locally advanced or metastatic

• Relapsed or refractory with at least 2 prior lines of therapy and for which no standard of care treatment options are available

• Radiographically measurable disease

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Life expectancy, in the opinion of the Investigator, of ≥ 3 months

• Adequate marrow reserve, renal function, and hepatic function

• Taper of ≥ 2 weeks from high-dose systemic corticosteroids (however, low dose corticosteroids ≤ 25 mg prednisone or equivalent daily are permitted in consultation with the Medical Monitor)

• Willing to provide archival tumor tissue samples or agree to a baseline biopsy if not available

• Willing to undergo an on-treatment biopsy if clinically feasible and not contraindicated at the time of procedure